APR Sept/Oct 2023 - 100

»
BIOPHARMACEUTICAL
»
In life sciences hotspots, real estate investors and developers have
found success converting single company campuses into dynamic
multi-tenant parks. For example, several years ago, GlaxoSmithKline
sold its campus in Research Triangle Park to Karlin Asset Management,
which assembled the parcel with the DowDuPont and Ellis DNC
campuses to create the 638-acre Research Triangle Park. Karlin
invested $80 million in building upgrades and amenities to eventually
attract tenants such as Duke Health and Lab Corp.
In another creative development, a life sciences company sold the bulk
of its campus to a multifamily developer while continuing to occupy an
office building on the site. To eliminate an overly branded, corporate
campus atmosphere, the company transformed the first floor of the
office building into a welcoming public facility that includes a library,
food services and group exercise space for the larger community.
These examples illustrate how companies have found creative uses
for underutilized space. The pace of change in the world today
opens many possibilities for legacy campuses, such as repurposing
older buildings for biomanufacturing, e-commerce logistics
facilities, multifamily neighborhoods, warehouse development and
more. No matter what route a company takes, giving new life to an
old campus presents a tremendous opportunity to enhance culture
and reinforce quality.
How Enlivening a Campus Enhances
Quality Culture
Whether
an
organization
enlivens
attitudes and behaviors that promote a dedication to excellence and
continuous improvement.
Uniting Quality Expectations on a
Shared Campus
its campus through social
events, wellness amenities or more transformative initiatives such
as developing a multi-tenant innovation park or live-work-play
community, its effort can have an unexpected indirect benefit:
enhancing its campus quality culture.
Quality assurance ranks among the top priorities for every company
in the highly regulated life sciences industry. Maintaining consistent
quality requires something that goes beyond the act of checking
boxes for compliance. It requires adapting quality as a core value to
support a culture where everyone - from scientists to custodial staff
- prioritizes quality in everything they do.
Nothing enhances quality culture quite like a beautiful, dynamic
facility where people enjoy spending time. Employees tend to
produce their best work when they enjoy coming to the campus and
thrive in their environment. That's because when people don't want to
lose something they love, they outperform to keep it. Having pride in
one's workplace can deepen commitment to the company's purpose
and reinforce each individual's role in maintaining quality.
Working in a multi-tenant environment, where employees can
network with others in the industry, has the potential to enhance
quality culture even further. People can meet face-to-face to discuss
best practices and industry trends, sparking new ideas and fresh
ways of approaching old problems. Organizations can also plan
community events and friendly competitions focused on qualityrelated
themes. This collaborative spirit
strengthens the values,
100 |
| September/October 2023
Overall, I believe the benefits of a dynamic, multi-tenant environment
have great potential to enhance quality culture, outweighing any
challenges that may emerge. However, bringing outside organizations
or other community members onto a legacy company campus
introduces a few compliance-related complexities.
The issues arise around shared regulated spaces, utilities and support
services, such as utility plants, shared warehouses, pest control
and security services. A proactive approach helps ensure that these
utilities, services and spaces are managed appropriately to address
each organization's unique compliance requirements. The first step is
to identify an owner that is ultimately responsible for the operations,
performance, maintenance and quality. The responsible party is
typically the landlord who owns the facility, but sometimes a space
such as a shared warehouse or a central utility building may be
managed by a tenant.
To ensure that everyone has the same understanding of quality
expectations of regulated systems, the owner and all tenants should
establish an agreement that lays out all expectations for how the
space or service must be managed to provide compliance.
The agreement must also set forth the involved parties' mutual
understandings regarding certain responsibilities, specifying how
each duty will be managed, supported, and maintained against the
highest quality standards. This agreement should also specify relevant
regulatory bodies because each company occupying a shared campus
may face different compliance obligations based on their products
and where they sell them. For example, a company that exports its
products to the UK, Latin America or other geographies faces different
regulations than one that sells only in the US.
Additionally, the agreement should lay out the requirements for how
the space, system or service must be managed. No issue is too small
- the more specific the requirements are, the better. The following
examples illustrate some sample issues that might be covered by a
quality agreement in a shared campus:
* Central utility plant: Depending on the type of companies
operating on campus, a plant may provide a variety of utility
services, such as chilled water, steam, compressed air, purified
water and more. Many of those utilities may be classified as
FDA-regulated services by some companies but not others,
making it imperative that the quality agreement establish which
utilities are considered regulated. Then the agreement can
outline the roles and responsibilities to comply with regulatory
expectations, such as operational parameter monitoring,
sampling of the utilities and a well-documented preventative
maintenance plan.

APR Sept/Oct 2023

Table of Contents for the Digital Edition of APR Sept/Oct 2023

INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
Facility Tour - Eurofins BioPharma Product Testing
ROUNDTABLE - Drug Delivery
MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
WHITEPAPER - Leveraging Analytical Technology Process for CMC
BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - Cover1
APR Sept/Oct 2023 - Cover2
APR Sept/Oct 2023 - 1
APR Sept/Oct 2023 - 2
APR Sept/Oct 2023 - 3
APR Sept/Oct 2023 - 4
APR Sept/Oct 2023 - 5
APR Sept/Oct 2023 - 6
APR Sept/Oct 2023 - 7
APR Sept/Oct 2023 - 8
APR Sept/Oct 2023 - 9
APR Sept/Oct 2023 - 10
APR Sept/Oct 2023 - 11
APR Sept/Oct 2023 - 12
APR Sept/Oct 2023 - 13
APR Sept/Oct 2023 - 14
APR Sept/Oct 2023 - 15
APR Sept/Oct 2023 - 16
APR Sept/Oct 2023 - 17
APR Sept/Oct 2023 - 18
APR Sept/Oct 2023 - 19
APR Sept/Oct 2023 - 20
APR Sept/Oct 2023 - 21
APR Sept/Oct 2023 - 22
APR Sept/Oct 2023 - 23
APR Sept/Oct 2023 - 24
APR Sept/Oct 2023 - 25
APR Sept/Oct 2023 - 26
APR Sept/Oct 2023 - 27
APR Sept/Oct 2023 - 28
APR Sept/Oct 2023 - 29
APR Sept/Oct 2023 - 30
APR Sept/Oct 2023 - INSIDER INSIGHT - From Guidelines to Standards: Why Comprehensive AI Regulation is Essential to Spurring Innovation
APR Sept/Oct 2023 - 32
APR Sept/Oct 2023 - 33
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Aseptic Process Simulation: Cell and Gene Therapy Manufacture
APR Sept/Oct 2023 - 35
APR Sept/Oct 2023 - 36
APR Sept/Oct 2023 - 37
APR Sept/Oct 2023 - 38
APR Sept/Oct 2023 - 39
APR Sept/Oct 2023 - 40
APR Sept/Oct 2023 - 41
APR Sept/Oct 2023 - 42
APR Sept/Oct 2023 - 43
APR Sept/Oct 2023 - FORMULATION & DEVELOPMENT - Challenges of Analytical Validation for ATMPs
APR Sept/Oct 2023 - 45
APR Sept/Oct 2023 - 46
APR Sept/Oct 2023 - 47
APR Sept/Oct 2023 - 48
APR Sept/Oct 2023 - 49
APR Sept/Oct 2023 - QC Corner - The Intricacies of Testing for Mycoplasmas in Cell Culture Systems
APR Sept/Oct 2023 - 51
APR Sept/Oct 2023 - MICROBIOLOGY - Standardized, Scalable And Efficient: Producing Recombinant Factor C to Quality Standards
APR Sept/Oct 2023 - 53
APR Sept/Oct 2023 - 54
APR Sept/Oct 2023 - 55
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - R Code to Estimate Probability of Passing USP Dissolution Test
APR Sept/Oct 2023 - 57
APR Sept/Oct 2023 - 58
APR Sept/Oct 2023 - 59
APR Sept/Oct 2023 - 60
APR Sept/Oct 2023 - 61
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Cloud Computing for Drug Discovery: The Time is Now
APR Sept/Oct 2023 - 63
APR Sept/Oct 2023 - 64
APR Sept/Oct 2023 - 65
APR Sept/Oct 2023 - 66
APR Sept/Oct 2023 - 67
APR Sept/Oct 2023 - CGT CIRCUIT - Navigating the Complex Testing Strategies for Viral Vector-based Gene Therapies
APR Sept/Oct 2023 - 69
APR Sept/Oct 2023 - MANUFACTURING - Simplifying Finished Product Manufacturer Site Transfer Variations
APR Sept/Oct 2023 - 71
APR Sept/Oct 2023 - 72
APR Sept/Oct 2023 - 73
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - Advancing Regulatory Compliance with Natural Language Processing
APR Sept/Oct 2023 - 75
APR Sept/Oct 2023 - 76
APR Sept/Oct 2023 - 77
APR Sept/Oct 2023 - DRUG DELIVERY - Finding a Greater Vantage Point for Creating Green Therapies
APR Sept/Oct 2023 - 79
APR Sept/Oct 2023 - 80
APR Sept/Oct 2023 - 81
APR Sept/Oct 2023 - WHITEPAPER - Microbial Testing for the Pharmaceutical Industry
APR Sept/Oct 2023 - 83
APR Sept/Oct 2023 - 84
APR Sept/Oct 2023 - 85
APR Sept/Oct 2023 - Facility Tour - Eurofins BioPharma Product Testing
APR Sept/Oct 2023 - 87
APR Sept/Oct 2023 - 88
APR Sept/Oct 2023 - ROUNDTABLE - Drug Delivery
APR Sept/Oct 2023 - 90
APR Sept/Oct 2023 - 91
APR Sept/Oct 2023 - MANUFACTURING - Accelerating Biologics R&D with Unified Software and Data Flows
APR Sept/Oct 2023 - 93
APR Sept/Oct 2023 - An Interview with Jason Downing, Senior Product Manager, TriLink BioTechnologies®
APR Sept/Oct 2023 - 95
APR Sept/Oct 2023 - FORMULATION AND DEVELOPMENT - The Role of Data in the Pharmaceutical Lifecycle
APR Sept/Oct 2023 - 97
APR Sept/Oct 2023 - 98
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Uniting Quality Expectations on Reinvigorated Biopharma Campuses
APR Sept/Oct 2023 - 100
APR Sept/Oct 2023 - 101
APR Sept/Oct 2023 - WHITEPAPER - VITAMIN C – Tableting with LUBRITAB® RBW Lubricant
APR Sept/Oct 2023 - 103
APR Sept/Oct 2023 - WHITEPAPER - Leveraging Analytical Technology Process for CMC
APR Sept/Oct 2023 - 105
APR Sept/Oct 2023 - 106
APR Sept/Oct 2023 - BIOPHARMACEUTICAL - Maximizing the Commercialization Potential of Cell and Gene Therapies
APR Sept/Oct 2023 - 108
APR Sept/Oct 2023 - 109
APR Sept/Oct 2023 - MICROBIOLOGY - Comments on Aseptic Process Simulation (APS) in the New EU GMP Annex 1
APR Sept/Oct 2023 - 111
APR Sept/Oct 2023 - 112
APR Sept/Oct 2023 - 113
APR Sept/Oct 2023 - VENDOR VIEWPOINT - Continuous & Intervention-Free Microbial Monitoring
APR Sept/Oct 2023 - 115
APR Sept/Oct 2023 - 116
APR Sept/Oct 2023 - 117
APR Sept/Oct 2023 - 118
APR Sept/Oct 2023 - 119
APR Sept/Oct 2023 - 120
APR Sept/Oct 2023 - Cover3
APR Sept/Oct 2023 - Cover4
https://www.nxtbookmedia.com